soul trial oral semaglutide cardiovascular outcomes 2024 results nejm π§Ώ is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM The SOUL trial (Semaglutide Cardiovascular
Description
Studies published in the Journal of the American Academy of Dermatology , suggest that while some improvement can be seen in the first few months, significant results typically take longer
Suga, T
This convenience enhances adherence to the treatment regimen, which is a critical factor in achieving and maintaining weight loss
Focus on bland foods that are easy to digest
Keep entirely secure from non-laboratory personnel
So, its safety and efficacy remain uncertain
